论文部分内容阅读
目的探讨注射用盐酸苯达莫司汀治疗利妥昔单抗耐药的B细胞惰性淋巴瘤的临床疗效。方法选取利妥昔单抗耐药的B细胞惰性淋巴瘤患者32例,给予注射盐酸苯达莫司汀,观察并分析患者近期疗效、远期疗效以及不良反应发生情况。结果 32例患者近期疗效总有效率为84.4%;不良反应为骨髓抑制、胃肠道反应和感染;随访2年,患者中位缓解持续时间为10个月,1例患者因疾病进展而病死。结论注射用盐酸苯达莫司汀治疗妥昔单抗耐药的B细胞惰性淋巴瘤患者具有明显疗效。
Objective To investigate the clinical efficacy of bendamustine hydrochloride for the treatment of rituximab-resistant B-cell lymphomas. Methods Thirty-two patients with active B-cell lymphoma who were resistant to rituximab were selected and injected with bendamustine hydrochloride. The short-term efficacy, long-term efficacy and adverse reactions were observed and analyzed. Results The total effective rate of the 32 patients was 84.4%. The adverse reactions were myelosuppression, gastrointestinal reaction and infection. The patients were followed up for 2 years. The duration of the median remission was 10 months. One patient died of disease progression. Conclusion Bendamustine hydrochloride injection has a significant effect in the treatment of patients with idiopathic B-cell lymphoma.